Literature DB >> 12496860

Genetic predisposition to prostate cancer.

R A Eeles1.   

Abstract

Prostate cancer has been known to run in families for about 40 years and epidemiological studies have demonstrated an increased risk to close relatives of cases. This risk rises markedly when the closeness and number of cases in a cluster increases. There has been considerable debate about the genetic model, in particular whether there is a commoner lower penetrance (moderately increased risk of the disease due to the gene(s)) in addition to contribution from high risk genes. For the first time, molecular results are starting to emerge, indicating the location of high risk genes. These have shown that there is evidence for more than one site of a high risk, gene two sites on chromosome 1 and one on chromosome X. These do not account for all clusters of prostate cancer cases and further genes remain to be discovered. This article also outlines the contribution of the numerous collaborators in the British Prostate Group to the UK Familial Prostate Cancer Study.

Entities:  

Year:  1999        PMID: 12496860     DOI: 10.1038/sj.pcan.4500279

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  20 in total

Review 1.  A genetic-based approach to personalized prostate cancer screening and treatment.

Authors:  Brian T Helfand; William J Catalona; Jianfeng Xu
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.

Authors:  Brian T Helfand; Haitao Chen; Richard J Fantus; Carly A Conran; Charles B Brendler; Siquan Lilly Zheng; Patrick C Walsh; William B Isaacs; Jianfeng Xu
Journal:  Prostate       Date:  2018-06-19       Impact factor: 4.104

3.  Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study.

Authors:  David Margel; Ofer Benjaminov; Rachel Ozalvo; Liat Shavit Grievink; Inbal Kedar; Rinat Yerushalmi; Irit Ben-Aharon; Victoria Neiman; Ofer Yossepowitch; Daniel Kedar; Zohar Levy; Mordechai Shohat; Baruch Brenner; Jack Baniel; Eli Rosenbaum
Journal:  BMC Cancer       Date:  2014-07-21       Impact factor: 4.430

4.  Prostate cancer: risk assessment and diagnostic approaches.

Authors:  L G Gomella; F Labrie; E J Gamito; M K Brawer
Journal:  Rev Urol       Date:  2001

5.  Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk.

Authors:  Robert J MacInnis; Daniel F Schmidt; Enes Makalic; Gianluca Severi; Liesel M FitzGerald; Matthias Reumann; Miroslaw K Kapuscinski; Adam Kowalczyk; Zeyu Zhou; Benjamin Goudey; Guoqi Qian; Quang M Bui; Daniel J Park; Adam Freeman; Melissa C Southey; Ali Amin Al Olama; Zsofia Kote-Jarai; Rosalind A Eeles; John L Hopper; Graham G Giles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-18       Impact factor: 4.254

Review 6.  A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer.

Authors:  Bradley King; Jana McHugh; Katie Snape
Journal:  Appl Clin Genet       Date:  2021-05-20

Review 7.  Molecular markers in prostate cancer. Part I: predicting lethality.

Authors:  Sachin Agrawal; William D Dunsmuir
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

8.  Mutation analysis of the MSMB gene in familial prostate cancer.

Authors:  Z Kote-Jarai; D Leongamornlert; M Tymrakiewicz; H Field; M Guy; A A Al Olama; J Morrison; L O'Brien; R Wilkinson; A Hall; E Sawyer; K Muir; F Hamdy; J Donovan; D Neal; D Easton; R Eeles
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

9.  Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.

Authors:  Jeffrey C Francis; Afshan McCarthy; Martin K Thomsen; Alan Ashworth; Amanda Swain
Journal:  PLoS Genet       Date:  2010-06-24       Impact factor: 5.917

10.  Disclosure of genetics research results after the death of the patient participant: a qualitative study of the impact on relatives.

Authors:  E Ormondroyd; C Moynihan; M Watson; C Foster; S Davolls; A Ardern-Jones; R Eeles
Journal:  J Genet Couns       Date:  2007-05-11       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.